Neurocrine Biosciences

View All

huntingtons-disease-treatment
A Turning Point: INGREZZA’s Impact on Huntington’s Disease Treatment and the Rise of Novel Therapies

Huntington’s disease is an incurable, rare genetic, progressive neurodegenerative disorder. According to the National Organization for Rare Disorders (NORD), about 30,000 people in the United States have Huntington’s disease, and another 200,000 are at risk of developing the condition. As per DelveInsight analy...

Find More

parkinson's
Voyager clears Neurocrine deal; Anthem speeds up launch; Lilly rushed its deal

Voyager clears Neurocrine agreement for Parkinson's gene therapy Voyager Therapeutics is signing a collaboration agreement with Neurocrine Biosciences that will remunerate the Cambridge, Massachusetts-based biotech USD 165 million upfront. In return, Neurocrine benefits certain rights to four gene therapy progra...

Find More